Search research articles
Contact Us
Filters
Showing results (11-20 of 47) with videos related to
Page
of 5
Sort By:
Journal of Medicinal Chemistry
|
June 25, 2004
Fragment-based drug discovery
Daniel A Erlanson, Robert S McDowell, Tom O'Brien
Cell Chemical Biology
|
November 29, 2018
Fragment-Based Drug Discovery: Advancing Fragments in the Absence of Crystal Structures
Daniel A Erlanson, Ben J Davis, Wolfgang Jahnke
Organic Letters
|
December 1, 2006
Selective reduction of peptide isothiazolidin-3-ones
Timothy P Shiau, Daniel A Erlanson, Eric M Gordon
The Journal of Pharmacology and Experimental Therapeutics
|
October 19, 2013
A novel and potent inhibitor of dimethylarginine dimethylaminohydrolase: a modulator of cardiovascular nitric oxide
Yohannes T Ghebremariam, Daniel A Erlanson, John P Cooke
Annual Review of Biophysics and Biomolecular Structure
|
May 14, 2004
Tethering: fragment-based drug discovery
Daniel A Erlanson, James A Wells, Andrew C Braisted
RSC Medicinal Chemistry
|
December 23, 2022
Introduction to the themed collection on fragment-based drug discovery
David C Rees, Anna K H Hirsch, Daniel A Erlanson
Journal of Biomolecular Screening
|
March 31, 2012
Development of a dimethylarginine dimethylaminohydrolase (DDAH) assay for high-throughput chemical screening
Yohannes T Ghebremariam, Daniel A Erlanson, Keisuke Yamada, et al.
Journal of Medicinal Chemistry
|
October 15, 2016
Fragment-to-Lead Medicinal Chemistry Publications in 2015
Christopher N Johnson, Daniel A Erlanson, Christopher W Murray, et al.
Nature Reviews. Drug Discovery
|
July 16, 2016
Twenty years on: the impact of fragments on drug discovery
Daniel A Erlanson, Stephen W Fesik, Roderick E Hubbard, et al.
Journal of Medicinal Chemistry
|
November 1, 2017
Fragment-to-Lead Medicinal Chemistry Publications in 2016
Christopher N Johnson, Daniel A Erlanson, Wolfgang Jahnke, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 47) with videos related to
Sort By:
Page
of 5
Journal of Medicinal Chemistry
|
June 25, 2004
Fragment-based drug discovery
Daniel A Erlanson, Robert S McDowell, Tom O'Brien
Cell Chemical Biology
|
November 29, 2018
Fragment-Based Drug Discovery: Advancing Fragments in the Absence of Crystal Structures
Daniel A Erlanson, Ben J Davis, Wolfgang Jahnke
Organic Letters
|
December 1, 2006
Selective reduction of peptide isothiazolidin-3-ones
Timothy P Shiau, Daniel A Erlanson, Eric M Gordon
The Journal of Pharmacology and Experimental Therapeutics
|
October 19, 2013
A novel and potent inhibitor of dimethylarginine dimethylaminohydrolase: a modulator of cardiovascular nitric oxide
Yohannes T Ghebremariam, Daniel A Erlanson, John P Cooke
Annual Review of Biophysics and Biomolecular Structure
|
May 14, 2004
Tethering: fragment-based drug discovery
Daniel A Erlanson, James A Wells, Andrew C Braisted
RSC Medicinal Chemistry
|
December 23, 2022
Introduction to the themed collection on fragment-based drug discovery
David C Rees, Anna K H Hirsch, Daniel A Erlanson
Journal of Biomolecular Screening
|
March 31, 2012
Development of a dimethylarginine dimethylaminohydrolase (DDAH) assay for high-throughput chemical screening
Yohannes T Ghebremariam, Daniel A Erlanson, Keisuke Yamada, et al.
Journal of Medicinal Chemistry
|
October 15, 2016
Fragment-to-Lead Medicinal Chemistry Publications in 2015
Christopher N Johnson, Daniel A Erlanson, Christopher W Murray, et al.
Nature Reviews. Drug Discovery
|
July 16, 2016
Twenty years on: the impact of fragments on drug discovery
Daniel A Erlanson, Stephen W Fesik, Roderick E Hubbard, et al.
Journal of Medicinal Chemistry
|
November 1, 2017
Fragment-to-Lead Medicinal Chemistry Publications in 2016
Christopher N Johnson, Daniel A Erlanson, Wolfgang Jahnke, et al.
Page
of 5